Search research articles
Contact Us
Filters
Showing results (21-30 of 139) with videos related to
Page
of 14
Sort By:
Arthritis Research & Therapy
|
October 3, 2008
Virally associated arthritis 2008: clinical, epidemiologic, and pathophysiologic considerations
Dimitrios Vassilopoulos, Leonard H Calabrese
Current Opinion in Rheumatology
|
July 18, 2020
Editorial: Reflections on rheumatological aspects of COVID-19
Leonard H Calabrese, Cassandra Calabrese
Cleveland Clinic Journal of Medicine
|
July 11, 2020
Cytokine release syndrome and the prospects for immunotherapy with COVID-19. Part 2: The role of interleukin 1
Leonard H Calabrese, Cassandra Calabrese
Arthritis and Rheumatism
|
March 29, 2002
Hepatitis C virus infection and vasculitis: implications of antiviral and immunosuppressive therapies
Dimitrios Vassilopoulos, Leonard H Calabrese
Current Opinion in Rheumatology
|
October 6, 2007
Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections
Dimitrios Vassilopoulos, Leonard H Calabrese
Cleveland Clinic Journal of Medicine
|
April 5, 2012
Q: Should I order an anti-CCP antibody test to diagnose rheumatoid arthritis?
Nilanjana Bose, Leonard H Calabrese
Nature Reviews. Rheumatology
|
August 4, 2009
Therapy: Targeted but not trouble-free: efalizumab and PML
Eamonn S Molloy, Leonard H Calabrese
Rheumatic Diseases Clinics of North America
|
November 29, 2016
Infection and Malignancy in Rheumatic Diseases
Kevin L Winthrop, Leonard H Calabrese
Annals of the Rheumatic Diseases
|
September 7, 2011
Let the fog be lifted: screening for hepatitis B virus before biological therapy
Kevin L Winthrop, Leonard H Calabrese
Nature Reviews. Rheumatology
|
August 20, 2014
IL-6 biology: implications for clinical targeting in rheumatic disease
Leonard H Calabrese, Stefan Rose-John
Page
of 14
Search research articles
Search
Showing results (21-30 of 139) with videos related to
Sort By:
Page
of 14
Arthritis Research & Therapy
|
October 3, 2008
Virally associated arthritis 2008: clinical, epidemiologic, and pathophysiologic considerations
Dimitrios Vassilopoulos, Leonard H Calabrese
Current Opinion in Rheumatology
|
July 18, 2020
Editorial: Reflections on rheumatological aspects of COVID-19
Leonard H Calabrese, Cassandra Calabrese
Cleveland Clinic Journal of Medicine
|
July 11, 2020
Cytokine release syndrome and the prospects for immunotherapy with COVID-19. Part 2: The role of interleukin 1
Leonard H Calabrese, Cassandra Calabrese
Arthritis and Rheumatism
|
March 29, 2002
Hepatitis C virus infection and vasculitis: implications of antiviral and immunosuppressive therapies
Dimitrios Vassilopoulos, Leonard H Calabrese
Current Opinion in Rheumatology
|
October 6, 2007
Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections
Dimitrios Vassilopoulos, Leonard H Calabrese
Cleveland Clinic Journal of Medicine
|
April 5, 2012
Q: Should I order an anti-CCP antibody test to diagnose rheumatoid arthritis?
Nilanjana Bose, Leonard H Calabrese
Nature Reviews. Rheumatology
|
August 4, 2009
Therapy: Targeted but not trouble-free: efalizumab and PML
Eamonn S Molloy, Leonard H Calabrese
Rheumatic Diseases Clinics of North America
|
November 29, 2016
Infection and Malignancy in Rheumatic Diseases
Kevin L Winthrop, Leonard H Calabrese
Annals of the Rheumatic Diseases
|
September 7, 2011
Let the fog be lifted: screening for hepatitis B virus before biological therapy
Kevin L Winthrop, Leonard H Calabrese
Nature Reviews. Rheumatology
|
August 20, 2014
IL-6 biology: implications for clinical targeting in rheumatic disease
Leonard H Calabrese, Stefan Rose-John
Page
of 14